Related Experiment Video

Updated: Jun 21, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 31, 2013

[Monoclonal antibody A12 against gastric cancer produced in immuno-reconstituted nude mice]

S M Wei1

  • 1Beijing Institute for Cancer Research.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|July 1, 1992
PubMed

A monoclonal antibody (mAb) A12 against gastric cancer was prepared in immuno-reconstituted nude mice from human ductal adenocarcinoma of stomach, Sy86B. mAb A12 could react with the majority of gastric cancer tissues (24/27-88.9%) but only cross react with a few normal tissues tested. The corresponding antigen of mAb A12 (antigen A12) was expressed at higher levels and usually in more than 50% of the cancer cells. mAb A12 may be a valid preparation in targeting therapy of gastric cancer. Preliminary analysis of antigen A12 showed that it is a oncofetal antigen probably of glycolipid or glycoprotein in nature.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines08:42

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines

Published on: July 19, 2019

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...